Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057133 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
A Phase 1 study of Breast Neoplasms, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 1
- Development phase
- 198
- Enrollment target
- 13
- Study locations
NCT02057133: Active Phase 1 study of Breast Neoplasms, sponsored by Eli Lilly and Company.
NCT02057133 is a Phase 1 study of Breast Neoplasms that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 198 participants, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (65% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02057133, a Phase 1 study of Breast Neoplasms, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 198 participants
- Enrollment target
- 13
- Study locations
Study Summary
This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to other parts of the body.
Primary Outcome
Number of participants with one or more drug-related adverse events
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Anastrozole
- DRUG Letrozole
- DRUG Exemestane
- DRUG LY2835219
Study Locations (13)
Tennessee
- Peggy and Charles Stephenson Oklahoma Cancer Center - Nashville
- Tennessee Oncology PLLC - Nashville
- Vanderbilt University Medical Center - Nashville
New York
- Columbia University College of Phys & Surgeons - New York
- Memorial Sloan Kettering Cancer Center - New York
Arkansas
- Highlands Oncology Group - Duplicate 2 - Rogers
California
- University of California - San Diego - La Jolla
Massachusetts
- Dana Farber Cancer Institute - Boston
Minnesota
- Mayo Clinic - Rochester
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Oregon
- Providence Cancer Center Oncology Hematology Care - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2014-03-10 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
What the registry record for NCT02057133 still lists
NCT02057133 is an interventional study that assigns participants to a tested intervention. The registered 198 participants enrollment target is mid-sized for trials with a published cap, below the 567-participant average among 97 other Breast Neoplasms trials with a reported enrollment target (65% lower).
The record links to 1 condition, with Breast Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Tamoxifen is the first listed.
NCT02057133 lists 13 locations in 10 states (Tennessee, New York, Arkansas).
Frequently Asked Questions
What is clinical trial NCT02057133 about?
NCT02057133 is a clinical study titled "A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread". This study evaluates the safety of abemaciclib in combination therapies (letrozole, anastrozole, tamoxifen, exemestane, exemestane plus everolimus, trastuzumab, LY3023414 plus fulvestrant, pertuzumab plus trastuzumab with loperamide, or ongoing endocrine therapy) for breast cancer that has spread to...
What is the current status of trial NCT02057133?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 198 participants. The study started on 2014-03-10. Estimated completion is 2026-12.
What conditions does trial NCT02057133 study?
This clinical trial studies the following conditions: Breast Neoplasms.
What interventions are being tested in trial NCT02057133?
The interventions under investigation include: Tamoxifen (DRUG), Anastrozole (DRUG), Letrozole (DRUG), Exemestane (DRUG), LY2835219 (DRUG).
Who is sponsoring clinical trial NCT02057133?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02057133 being conducted?
This trial has 13 study locations across Arkansas, California, Massachusetts, Minnesota, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02057133's enrollment target sits among peer trials
198 40th of 97 higher than 58 of 97 other Breast Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Focused Ultrasound and Gemcitabine in Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RECRUITING · Phase 1
-
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
RECRUITING · Phase 1
-
A Study of DM001 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
- NCT05585190 · 198 participants · NA
Stand Up for Your Health with a Sit-stand Desk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI